NAD+ Dosage: Oral, Injection & IV Dosing Guide (2026)

Key Takeaways

• Oral NMN at 250 to 1,000 mg/day and oral NR at 300 to 1,000 mg/day have been tested in published human trials. Both roughly double blood NAD+ within 14 days.
• Injectable NAD+ dosing (50 to 200 mg subcutaneous, 2 to 3 times per week) comes from clinic protocols, not from controlled trials. No RCT has established an optimal dose for any injectable route.
• Starting low (250 mg/day oral NMN or 50 mg/session injectable) and increasing gradually over 2 to 4 weeks is the most common clinical recommendation.
• "NAD+ peptide dosage" and "NAD+ injection dosage" refer to the same molecule. NAD+ is not a peptide; the "peptide" label comes from marketing.

Oral NMN Dosage: What Clinical Trials Used

This is where the evidence is. If you want a dosage backed by controlled human data, oral NMN is the starting point.

Across 12+ published randomized controlled trials, NMN has been tested at doses ranging from 100 mg/day to 1,250 mg/day. The most commonly studied doses cluster between 250 mg and 600 mg per day, with treatment periods of 4 to 12 weeks.

The January 2026 head-to-head trial (Christen et al., Nature Metabolism, 65 participants) used 1,000 mg/day and found that NMN approximately doubled circulating NAD+ by day 14. Yoshino et al. (2021, Science) used 250 mg/day for 10 weeks and found improved skeletal muscle insulin signaling in overweight postmenopausal women. The July 2026 meta-analysis pooled safety data across all NMN RCTs and found no difference in adverse event rates between NMN and placebo at any tested dose.

If you're starting NMN for the first time, 250 to 500 mg per day is the range most aligned with the bulk of published evidence. There is no clinical reason to start at 1,000 mg. Higher doses have been tested and appear safe, but they haven't been shown to produce proportionally better outcomes. The 2024 Zhang meta-analysis explicitly warned that "an exaggeration of the benefits of NMN supplementation may exist in the field."

Timing: most trials had participants take NMN in the morning. One RCT found that 250 mg/day improved afternoon drowsiness and sleep quality in older adults, which suggests a morning dose may align better with circadian NAD+ rhythms. Taking NMN with food can reduce the mild GI discomfort that some people experience on an empty stomach.

Oral NR Dosage

NR (nicotinamide riboside) has been studied at 100 to 2,000 mg/day across 20+ human RCTs. The most common research doses are 300 mg and 1,000 mg per day. Martens et al. (2018, Nature Communications) showed that 1,000 mg/day of NR was well tolerated and elevated NAD+ metabolites in healthy middle-aged and older adults. The Christen 2026 trial used 1,000 mg/day and found NR roughly doubled blood NAD+ at 14 days, comparable to NMN at the same dose.

The February 2026 Berven et al. pharmacokinetic study found that NR raised blood NAD+ substantially more than NMN (roughly 161% vs 69%). That single study, if replicated, would suggest NR might be more potent per milligram for blood NAD+ elevation. But one pharmacokinetic trial does not override the broader evidence base, and "more blood NAD+" does not automatically mean "better clinical outcomes."

For NR, 300 to 500 mg/day is a reasonable starting dose. The commercially available Tru Niagen product, which has the most extensive clinical trial portfolio of any NR brand, uses 300 mg/day as its standard dose.

One nuance that matters for NR dosing: Martens et al. (2018) tested 1,000 mg/day of NR (split into 500 mg twice daily) for 6 weeks in healthy middle-aged and older adults and found it well tolerated with elevated NAD+ metabolites. That study used a twice-daily split dose. Whether splitting the dose matters for absorption or efficacy compared to taking it all at once has not been directly compared. In practice, most users take their full daily NR dose in the morning in a single serving. If you experience GI discomfort at 500+ mg/day, splitting into two doses (morning and midday, not evening) may help by reducing the per-dose load on the GI tract.

NR and NMN are sometimes described as interchangeable. They're not. The Christen 2026 trial found both roughly doubled blood NAD+ at 14 days at 1,000 mg/day, but the Berven 2026 pharmacokinetic study found NR raised blood NAD+ substantially more than NMN (roughly 161% versus 69%). NR also reached brain NAD+ after 4 weeks, while NMN did not within the study period. These are single studies, not settled science, but they suggest the two precursors may not be equivalent at every level. If your primary interest is brain-specific NAD+ support, the Berven data gives NR a tentative edge. If you're optimizing for cost or convenience, NMN and NR are comparably priced and both work for blood NAD+ elevation.

Does a Higher Dose Mean Better Results?

This is the question behind every dosage search, and the answer from published data is a clear "not necessarily."

The Christen 2026 trial used 1,000 mg/day of both NMN and NR. Both approximately doubled blood NAD+ within 14 days. But Yoshino 2021 used only 250 mg/day of NMN for 10 weeks and produced the best-documented clinical outcome in the NMN literature: improved skeletal muscle insulin signaling in overweight postmenopausal women. The lower dose produced the more meaningful result.

Zhang et al. (2024) pooled data from 12 NMN RCTs (513 participants, doses ranging from 150 to 1,200 mg/day) and found that NMN reliably raised blood NAD+ across all tested doses. But here's the part that gets less attention: the meta-analysis found no significant effect on fasting glucose, triglycerides, total cholesterol, LDL-C, or HDL-C at any dose. NAD+ went up, but most downstream clinical markers didn't change. The authors explicitly warned about "exaggeration of the benefits of NMN supplementation."

What this means for your dosing decision: doubling the dose doubles your cost and doubles the amount of a compound your liver processes daily. Whether it doubles the benefit is unproven. The dose-response curve for NAD+ precursors in humans has not been mapped. We know 250 mg works for blood NAD+ elevation. We know 1,000 mg works too. We don't know that 1,000 mg produces twice the effect of 250 mg, because no trial has compared them head-to-head for clinical outcomes (only for NAD+ biomarker elevation, which is a proxy, not the endpoint most people care about).

A reasonable approach: start at 250 to 500 mg/day. Stay there for at least 8 weeks. If you're tracking biomarkers (a few companies now offer whole-blood NAD+ testing), reassess at that point. Only increase if your levels are below the range associated with benefit in published data. Don't increase just because someone on Reddit said they "feel better" at 1,000 mg. Subjective reports without blinding or placebo control tell you very little about pharmacology.

How to Tell If Your NAD+ Dose Is Working

This is where dosing advice gets uncomfortable, because the honest answer is: for most people taking oral precursors, there is no reliable way to tell from how you feel.

NAD+ is not caffeine. It doesn't produce an acute, noticeable effect in most users. Some people report more energy, better sleep, or faster exercise recovery within the first week. Others take NMN for months and feel nothing different. Both experiences are consistent with what clinical trials report: modest or null effects on most subjective measures, even when blood NAD+ levels clearly rise.

If you want objective confirmation that your dose is doing something, the only option is lab testing. Several companies (Jinfiniti, Chromadex's TruDiagnostic partnership) offer intracellular or whole-blood NAD+ testing. Jinfiniti's recommended optimal range is 40 to 100 micromoles. If your test comes back below 40 before supplementation and rises into that range after 4 to 8 weeks of oral NMN or NR, you have objective evidence the dose is working at the biomarker level. Whether that biomarker change translates to outcomes you can feel is the part clinical trials haven't reliably demonstrated.

What you should not do: keep increasing your dose because you're "not feeling it." The absence of a subjective response does not mean the compound isn't working. It might mean the effects are cellular and subclinical, exactly the kind of thing that matters for long-term aging but doesn't produce a perceptible sensation. Or it might mean your baseline NAD+ was fine and you didn't need supplementation in the first place. Lab testing is the only way to distinguish between these scenarios.

Age, Body Weight, and NAD+ Dosing

A common question: should older people take more? Should heavier people take more? The answer is that no published trial has established age- or weight-adjusted dosing for any NAD+ precursor. Every trial to date has used a fixed dose for all participants, regardless of age, sex, or body weight.

The theoretical case for age-adjusted dosing is straightforward. NAD+ levels decline roughly 10% per decade after age 40 (Massudi et al., 2012). A 70-year-old with 40 to 50% less NAD+ than a 30-year-old might need a larger dose to reach the same absolute level. But "might" isn't data, and no trial has tested whether 500 mg works differently in a 70-year-old than in a 45-year-old.

Body weight adjustment is even less studied. Most pharmaceutical drugs are dosed by weight or body surface area. NAD+ precursors haven't been. Whether a 60 kg woman and a 100 kg man respond equivalently to 500 mg of NMN is unknown. The trials typically recruited a mix of body types and reported aggregate results.

Until personalized dosing data exists, the pragmatic approach is to start at the standard dose (250 to 500 mg/day for NMN, 300 mg/day for NR) regardless of age or weight, test your NAD+ levels after 4 to 8 weeks, and adjust from there. This isn't elegant, but it's aligned with what the evidence currently supports.

NAD+ Injection Dosage

This is the section most people searching "NAD+ dosage" are looking for. Before the dosing details, one critical framing note: every injection dose listed below comes from clinic protocols or community practice, not from published randomized controlled trials. No RCT has established an optimal NAD+ injection dose for any indication.

Subcutaneous NAD+ injection dosage

Subcutaneous (SubQ) injection delivers NAD+ into the fat layer beneath the skin, typically in the abdomen or thigh. Absorption is slower than IV but faster than oral.

Common protocols from US telehealth providers and wellness clinics:

One clinic SOP (Walnut Creek Aesthetics, published January 2025) specifies: start at 50 mg subcutaneously once weekly for 4 weeks. If tolerated, increase to 100 mg once weekly. Maximum dose: 100 mg once weekly. That's on the conservative end. Other telehealth providers prescribe 100 to 200 mg two to three times per week, which delivers substantially more NAD+ per week.

The stinging at the injection site is dose-dependent and concentration-dependent. More concentrated solutions (above 50 mg/mL) sting more. Injecting slowly over 5 to 10 seconds and rotating sites between abdomen quadrants helps. Buffered formulations (pH-adjusted to 7.0-7.4) sting less than unbuffered preparations.

NAD+ injection dosage per day vs per week

"NAD+ injection dosage per day" (1,300/month searches) and "per week" (800/month) are both heavily searched because people want to know the total weekly load, not just the per-session amount.

At the standard maintenance protocol of 100 mg subcutaneous, 3 times per week, you're getting 300 mg of injectable NAD+ per week. That's roughly comparable to taking 250 to 500 mg of oral NMN per day (which delivers 1,750 to 3,500 mg per week of precursor material, though oral bioavailability is lower than direct injection).

The comparison is imperfect because injectable NAD+ bypasses digestion but still faces the challenge that NAD+ doesn't freely cross cell membranes. It likely requires extracellular conversion to NMN or NR before cellular uptake. So "injecting 300 mg of NAD+ per week" does not mean "300 mg of NAD+ reaches the inside of your cells per week." The pharmacokinetics of injectable NAD+ in humans have barely been characterized. An April 2026 preprint (Nkrumah-Elie et al., ChromaDex-funded, not yet peer-reviewed) reported the first Phase 1 pilot data on injectable NR and NAD+ across intramuscular, IV, and subcutaneous routes in 45 participants, but this is preliminary safety data, not a dosing study, and it awaits peer review.

IV NAD+ dosage

IV infusion delivers NAD+ directly into the bloodstream at higher doses than subcutaneous injection allows comfortably. Typical clinic protocols:

• Standard session: 250 to 500 mg infused over 2 to 4 hours
• High-dose session: 750 to 1,000 mg infused over 3 to 6 hours
• Frequency: weekly, biweekly, or monthly depending on the clinic's protocol and the patient's goals

The infusion rate matters more than the total dose for side effects. Pushing 500 mg over 1 hour causes more chest tightness, nausea, and flushing than the same 500 mg over 4 hours. Most clinics start with a slower drip and increase the rate based on patient tolerance.

A 2019 pilot study published in Frontiers in Aging Neuroscience found that urinary NAD+ levels jumped 538% during a six-hour IV infusion. That number sounds impressive until you realize what it means: a large fraction of the infused NAD+ was being excreted in urine rather than retained by cells. Direct IV delivery does not guarantee intracellular uptake.

NAD+ Reconstitution Basics

If you've been prescribed injectable NAD+ by a physician through a compounding pharmacy, the product typically arrives as a lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water before injection.

The reconstitution determines the concentration, and the concentration determines how many units you draw on an insulin syringe for your prescribed dose. Getting this math wrong changes your dose, so it matters.

The most common reconstitution for subcutaneous use: 5 mL of bacteriostatic water into a 500 mg vial, yielding 100 mg/mL. For a prescribed dose of 100 mg, you draw to the 100-unit mark on a U-100 insulin syringe (= 1.0 mL).

For lower-sting injections, some users prefer 10 mL of BAC water (50 mg/mL), but that means drawing 2 mL for a 100 mg dose, which exceeds a standard insulin syringe. You'd need a 3 mL syringe with a separate subcutaneous needle.

Important: This is reference information describing common reconstitution protocols, not a dosing guide. Injectable NAD+ requires a physician's prescription. Your prescribing doctor determines your dose, concentration, and frequency. Follow their instructions, not a chart from a website.

Stacking NAD+ Precursors: Does Combining Compounds Help?

"NAD+ and MOTS-c stack dosage" (150 monthly searches) and various "NMN + resveratrol" or "NMN + TMG" stacking questions come up frequently. The logic: if one compound raises NAD+ through one pathway, combining it with compounds that work through other pathways might produce a larger or more sustained effect.

David Sinclair's publicized regimen (NMN + resveratrol + metformin) popularized this approach. But the evidence behind stacking is thin. No published RCT has compared an NMN-only protocol against an NMN + resveratrol protocol, or an NMN + TMG protocol, in a head-to-head design. The individual components have data. The combinations don't.

TMG (trimethylglycine, also called betaine) is the most commonly recommended stack partner for NMN. The reasoning: NMN metabolism consumes methyl groups, and TMG is a methyl donor that replenishes them. In theory, adding TMG prevents NMN supplementation from depleting your methyl pool, which could affect homocysteine levels and epigenetic methylation. This is biologically plausible. It's also speculative. No human study has measured whether NMN supplementation at 250 to 1,000 mg/day actually depletes methyl groups enough to warrant TMG co-supplementation. If you add TMG, typical doses in studies are 500 to 3,000 mg/day.

Resveratrol is a polyphenol that activates SIRT1, the sirtuin that uses NAD+ as a substrate. The logic is that raising NAD+ (via NMN) while simultaneously activating SIRT1 (via resveratrol) gives the sirtuin both the fuel and the activation signal. This makes biochemical sense. In mice, the combination produced more dramatic effects than either compound alone. In humans, resveratrol has its own mixed clinical trial record (some positive insulin sensitivity findings, many null results), and the combination has not been tested. Typical resveratrol doses in trials: 150 to 500 mg/day.

Bottom line on stacking: if you want to stack, start with NMN alone at a dose that's proven to raise NAD+ (250 to 500 mg). Once you've established that baseline for 4 to 8 weeks, add one compound at a time (TMG or resveratrol, not both simultaneously) and track whether anything changes. This isn't a validated clinical approach. It's methodical self-experimentation with compounds that have individual safety data. Don't stack more than three compounds without discussing it with a healthcare provider, especially if you take prescription medications.

NAD+ Nasal Spray Dosage

NAD+ nasal sprays are sold through specialty compounding pharmacies and some online retailers. Typical formulations contain 50 to 100 mg of NAD+ per mL, with dosing at 1 to 2 sprays per nostril, once or twice daily. That works out to roughly 100 to 200 mg of NAD+ applied per day.

No published clinical trial has evaluated NAD+ nasal spray dosing, efficacy, or absorption. Whether NAD+ crosses the nasal mucosa in meaningful amounts is unstudied. The nasal route is plausible for smaller molecules (intranasal insulin at 5,808 Da and intranasal oxytocin at 1,007 Da are clinically validated), but NAD+ at 663 Da has not been specifically tested via this route in published research.

Anecdotally reported side effects include nasal irritation and burning. If you try nasal NAD+, you're essentially running your own experiment. There's no published dosing protocol to follow.

Dose Titration: How to Ramp Up (and When to Stop)

No published protocol specifies a standardized titration schedule for oral NMN or NR. But the clinical pharmacology principle is straightforward: start low, increase gradually, monitor for side effects, and stop escalating when you reach a dose that either produces the desired biomarker change or hits the ceiling of what's been tested.

A practical titration approach built from trial data:

Weeks 1 to 2: 250 mg/day (NMN) or 300 mg/day (NR). Take with breakfast. This is the most-studied starting dose and sits well within the safety envelope. Watch for GI discomfort. If it occurs, stick at this dose until it resolves before increasing.

Weeks 3 to 4: If tolerated, increase to 500 mg/day. This is the most common maintenance dose across the literature and a reasonable long-term target for most people. Many published trials used this dose for 8 to 12 weeks without issues.

Week 5 onward: If you have objective reasons to increase further (NAD+ lab test showing suboptimal levels, physician recommendation), you can go to 750 mg or 1,000 mg/day. The Christen 2026 trial tested 1,000 mg/day safely for 14 days. The July 2026 meta-analysis included doses up to 1,250 mg/day. Above 500 mg, you're in the upper range of what's been tested, with diminishing certainty about the risk-benefit ratio.

When to stop: if you experience persistent side effects (GI discomfort beyond the first week, headache, insomnia) that don't resolve by reducing the dose. If lab testing shows your NAD+ is already in the optimal range without supplementation. Or if you've been supplementing for several months and want to take a break to see whether you notice any difference. NAD+ precursors are not habit-forming, and there is no published evidence of a rebound effect (NAD+ levels crashing below pre-supplementation baseline after stopping).

For injectable NAD+, titration is simpler because your prescribing physician determines the schedule. The standard approach from clinic SOPs: start at 50 mg subcutaneous once weekly for 2 to 4 weeks. If tolerated, increase to 100 mg. Some protocols go to 200 mg for patients who respond well. Each increase should have at least a 2-week observation period before the next step up. Don't skip the titration just because you read about someone injecting 500 mg daily. That's at the extreme end of what clinics report, not a starting point.

What Happens When You Stop Taking NAD+?

People searching for dosage information often want to know: if I stop, do my NAD+ levels crash? Do I feel worse than before I started?

No published study has specifically tracked what happens to NAD+ levels after discontinuing NMN or NR supplementation. The Christen 2026 trial measured NAD+ at day 14 of supplementation but did not report a post-discontinuation washout period. What we know from NAD+ biology suggests that levels would gradually return to your pre-supplementation baseline over days to weeks, driven by the same factors (CD38 activity, PARP consumption, NAMPT decline) that caused the original deficit.

This means supplementation does not "fix" the underlying decline. It compensates for it while you're taking it. If you stop, the supply-demand imbalance that was there before returns. Whether you notice a subjective difference after stopping depends on whether you noticed a subjective difference while taking it, which most clinical trials found to be modest at best.

Anecdotally, some long-term users report feeling more fatigued or "foggy" for a week or two after stopping. This could be a real rebound effect, a nocebo response (expecting to feel worse), or simply the return of baseline aging-related NAD+ decline that the supplement had been masking. Without controlled data, it's impossible to distinguish between these.

If you plan to discontinue, tapering (cutting the dose in half for a week before stopping) is a reasonable precaution, though there's no clinical evidence that it's necessary. It's borrowed from general pharmacological practice, not from NAD+-specific data.

How Much NAD+ Should I Take?

That depends on three things: what you're trying to accomplish, how you plan to take it, and how much risk you're comfortable with.

If your goal is to raise NAD+ levels based on the strongest available evidence, start with oral NMN at 250 to 500 mg per day or oral NR at 300 mg per day. These doses sit in the sweet spot of the clinical trial data: enough to produce measurable NAD+ elevation, low enough to have established safety profiles, and affordable enough for long-term use. You can increase to 1,000 mg/day if you tolerate the lower dose and want to match the higher end of what trials have tested.

If you want injectable NAD+ because you've already tried oral precursors and want to explore direct delivery, work with a prescribing physician. A reasonable starting dose is 50 mg subcutaneous once weekly, increasing to 100 mg two to three times weekly based on tolerance. Don't skip the physician step. Compounded NAD+ quality varies between pharmacies, and you need someone who can order baseline labs and monitor your response.

If you're comparing cost, the math is clear. Oral NMN at 500 mg/day costs $30 to $60/month. Subcutaneous NAD+ at 100 mg three times weekly costs $200 to $500/month. IV NAD+ at one session per month costs $400 to $1,500. All three raise NAD+ in the blood. Only oral precursors have controlled trial data demonstrating it.

NAD+ Dosing Timing

Morning dosing is preferred for all routes. NAD+ directly influences circadian clock gene expression (CLOCK, BMAL1) through sirtuin activation. Your body's natural NAD+ levels peak during the active phase of the day and decline at night. Taking NAD+ precursors or injectable NAD+ in the morning aligns with this rhythm.

Several users and clinicians report that afternoon or evening dosing can cause restlessness or difficulty falling asleep, likely because activating cellular energy pathways late in the day conflicts with the body's shift toward rest mode. This hasn't been studied in an RCT, but the circadian biology supports morning dosing, and one trial that reported improved sleep quality used a morning dose.

For injectable NAD+, morning administration also allows any side effects (stinging, brief nausea) to resolve during the day rather than interfering with sleep.

Frequently Asked Questions

What is the recommended NAD+ dosage per day?

For oral NMN: 250 to 500 mg/day is the most common range in published trials. For oral NR: 300 mg/day is the standard commercial dose, with trials going up to 2,000 mg/day. For subcutaneous NAD+ injection: 50 to 200 mg per session (not daily; typically 2 to 3 times per week). There is no universally "recommended" dose because no regulatory body has established one.

How much NAD+ should I inject?

Follow your prescribing physician's instructions. Common starting doses are 50 mg subcutaneously once weekly, increasing to 100 mg two to three times weekly based on tolerance. Maximum doses in clinic protocols reach 200 to 500 mg per session, though higher doses have not been tested in controlled trials.

What is the NAD+ injection dosage chart for 500 mg vials?

Reconstitute with 5 mL bacteriostatic water for 100 mg/mL. For a 100 mg dose, draw to 100 units on a U-100 insulin syringe (1.0 mL). For a 50 mg dose, draw to 50 units (0.5 mL). For a lower-sting option, use 10 mL BAC water (50 mg/mL) and draw 2.0 mL for a 100 mg dose with a 3 mL syringe.

Is 250 mg or 500 mg NMN better?

Both doses have been tested in human trials. 250 mg/day produced measurable NAD+ elevation and was the dose used in the Yoshino 2021 insulin sensitivity trial. 500 mg/day is a common middle-ground dose. There is no published trial showing that 500 mg produces better clinical outcomes than 250 mg. Starting at 250 mg and increasing if desired after 2 to 4 weeks is the most evidence-aligned approach.

How often should I take NAD+?

Oral NMN or NR: once daily (morning). Subcutaneous injection: 2 to 3 times per week. IV infusion: weekly to monthly. NAD+ is a coenzyme, not a receptor agonist, so there is no desensitization concern that would require cycling on and off.

What is NAD+ nasal spray dosage?

Common formulations deliver 50 to 100 mg per mL, dosed at 1 to 2 sprays per nostril once or twice daily (roughly 100 to 200 mg/day). No published trial has established an optimal nasal dose. This delivery route lacks formal evidence.

Related Reading

• NAD+ Levels: How to Increase Them Naturally
• What Is NAD+? Benefits, Function & Why It Declines With Age
• NAD+ Side Effects: What Clinical Trials Report
• Is NAD+ a Peptide? No. Here's What It Actually Is
• NAD+ Injections: Benefits, Side Effects & Cost
• NAD+ IV Therapy: How It Works, Costs & Evidence
• NAD+ Supplements: Types, Evidence & How to Choose
• Best NAD+ Supplements in 2026
• NAD+ Patches: Do They Work?
• NMN Dosage: How Much Per Day?

References

1. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8:62-73. doi:10.1038/s42255-025-01421-8 View source (PubMed)
2. Nkrumah-Elie Y, Kwon J, Simpson S, et al. Preliminary safety analysis of two pilot clinical trials involving injections of Niagen, nicotinamide riboside chloride. medRxiv (preprint). 2026. doi:10.64898/2026.04.28.26352007 View source (medRxiv preprint)
3. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985 View source (PubMed)
4. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients. 2026;18(14). Published July 2026. View source (PubMed)
5. Zhang J, Poon ETC, Wong SHS. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis. Critical Reviews in Food Science and Nutrition. 2025;65(22):4382-4400. doi:10.1080/10408398.2024.2387324 View source (PubMed)
6. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. doi:10.1038/s41467-018-03421-7 View source (PubMed)
7. Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026;29(3):114764. doi:10.1016/j.isci.2026.114764 View source (PubMed)
8. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057 View source (PubMed)

Written by Tao Wu. Last reviewed September 2026. This article is for informational purposes and does not constitute medical advice. Talk to your doctor before starting any new supplement.